← Leaderboards
Moon H. Nahm
University Of Rochester
$6,216,138
Attributed
$6,216,138
Total exposure
7
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $1.1M · FY2006–24$2M$1.5M$1M$500K$0
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$6,216,138 · 7
By mechanism
R01$4,455,433 · 3
N01$986,080 · 2
R21$408,375 · 1
R56$366,250 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Rochester
Same institution · by research overlap
- Christopher S Anderson$406,688
Others in their field
Top investigators on “Streptococcus Pneumoniae”
- Jeffrey N. Weiser · New York University School Of Medicine$20,590,649
- Dallas Hughes · Novobiotic Pharmaceuticals, Llc$15,114,161
- Elaine Tuomanen · University Of Alabama At Birmingham$13,568,473
- Liise-Anne Pirofski · Yeshiva University$13,441,639
- Joseph P Mizgerd · Boston University Medical Campus$12,549,527
- Myron Max Levine · University Of Maryland Baltimore$12,500,000
Research focus
Streptococcus PneumoniaeSerotypingPathogenPolysaccharidesSerumChildYoung AdultElderlyAntibodiesVaccinesPrevalenceCapsule (Pharmacologic)Pneumococcal Conjugate VaccineAdultImmunityResearch PersonnelMutationProgramsInterestVaccinationPneumococcal InfectionsBiochemicalOpsoninBase
Grant awards (23)
Serogroup 19 capsule maleability leading to vaccine failure$222,750
R21 · FY2024 · AI · contact PI
Serogroup 19 capsule maleability leading to vaccine failure$185,625
R21 · FY2023 · AI · contact PI
Acquired deficiency of innate immunity (ficolin-2) among elderly adults$316,050
R01 · FY2019 · AG · contact PI
Acquired deficiency of innate immunity (ficolin-2) among elderly adults$316,050
R01 · FY2018 · AG · contact PI
Acquired deficiency of innate immunity (ficolin-2) among elderly adults$316,050
R01 · FY2017 · AG · contact PI
Acquired deficiency of innate immunity (ficolin-2) among elderly adults$316,050
R01 · FY2016 · AG · contact PI
Acquired deficiency of innate immunity (ficolin-2) among elderly adults$316,050
R01 · FY2015 · AG · contact PI
Pneumococcal capsule and host innate immunity$366,250
R56 · FY2012 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$243,974
R01 · FY2011 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$258,701
R01 · FY2010 · AI · contact PI
Respiratory Pathogens Reference Laboratory$586,184
N01 · FY2009 · AI · contact PI
Pneumococcal conjugate vaccines and old adults$281,682
R01 · FY2009 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$248,929
R01 · FY2009 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$12,969
R01 · FY2009 · AI · contact PI
Pneumococcal conjugate vaccines and old adults$281,653
R01 · FY2008 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$248,929
R01 · FY2008 · AI · contact PI
Pneumococcal conjugate vaccines and old adults$287,079
R01 · FY2007 · AI · contact PI
Impact of a new group 6 serotype on pneumococcal vaccines$249,250
R01 · FY2007 · AI · contact PI
Pneumococcal conjugate vaccines and old adults$317,465
R01 · FY2006 · AI · contact PI
IMMUNE RESPONSE TO S PNEUMONIAE CAPSULAR POLYSACCHARIDE$176,274
R01 · FY2001 · AI
IMMUNE RESPONSE TO S PNEUMONIAE CAPSULAR POLYSACCHARIDE$49,287
R01 · FY2001 · AI
PNEUMOCOCCAL REFERENCE LABORATORY$399,896
N01 · FY2000 · AI
IMMUNE RESPONSE TO S PNEUMONIAE CAPSULAR POLYSACCHARIDE$218,991
R01 · FY2000 · AI